Axsome Therapeutics Clocks Around 60% Topline Growth In Q1
1. AXSM's Q1 2025 revenues rose to $121.5 million, exceeding expectations. 2. Auvelity sales reached $96.2 million, an 80% year-over-year increase. 3. FDA approved Symbravo for migraine treatment, boosting future revenue potential. 4. Net loss decreased to $59.4 million, showing operational improvement year over year. 5. AXSM to submit sNDA for AXS-05 in AD agitation in Q3 2025.